Compare Stocks: JSPR, GANX, ATRA, and ACET

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$8.38	$8.35	$6.01 ▼ $17.44	$78.45M	1.6	86,834 shs	57,664 shs
ATRA Atara Biotherapeutics	$8.09	$9.40	$3.92 ▼ $19.15	$72.89M	0.12	55,414 shs	66,247 shs
GANX Gain Therapeutics	$2.12	$1.81	$1.51 ▼ $4.34	$92.52M	0.19	528,254 shs	517,606 shs
JSPR Jasper Therapeutics	$0.79	$0.59	$0.32 ▼ $3.14	$22.12M	3.02	798,981 shs	567,510 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	+5.01%	+3.20%	+11.73%	-20.04%
ATRA Atara Biotherapeutics	0.00%	-4.26%	-3.58%	-11.58%	-34.17%
GANX Gain Therapeutics	0.00%	+16.48%	+23.98%	+30.86%	+22.54%
JSPR Jasper Therapeutics	0.00%	+11.36%	-10.72%	-2.03%	-74.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$8.38	$8.35	$6.01 ▼ $17.44	$78.45M	1.6	86,834 shs	57,664 shs
ATRA Atara Biotherapeutics	$8.09	$9.40	$3.92 ▼ $19.15	$72.89M	0.12	55,414 shs	66,247 shs
GANX Gain Therapeutics	$2.12	$1.81	$1.51 ▼ $4.34	$92.52M	0.19	528,254 shs	517,606 shs
JSPR Jasper Therapeutics	$0.79	$0.59	$0.32 ▼ $3.14	$22.12M	3.02	798,981 shs	567,510 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	+5.01%	+3.20%	+11.73%	-20.04%
ATRA Atara Biotherapeutics	0.00%	-4.26%	-3.58%	-11.58%	-34.17%
GANX Gain Therapeutics	0.00%	+16.48%	+23.98%	+30.86%	+22.54%
JSPR Jasper Therapeutics	0.00%	+11.36%	-10.72%	-2.03%	-74.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.75	Moderate Buy	$46.80	458.47% Upside
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	17.43% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	253.77% Upside
JSPR Jasper Therapeutics	2.44	Hold	$8.17	933.62% Upside

Current Analyst Ratings Breakdown

Latest JSPR, GANX, ATRA, and ACET Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/11/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	JSPR Jasper Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
6/9/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
ATRA Atara Biotherapeutics	$120.77M	0.60	$4.87 per share	1.66	($5.34) per share	-1.51
GANX Gain Therapeutics	$50K	1,850.34	N/A	N/A	$0.48 per share	4.42
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/4/2026 (Estimated)
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	5.78	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
GANX Gain Therapeutics	-$20.16M	-$0.50	N/A	N/A	N/A	N/A	-161.59%	-118.36%	N/A
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-712.13%	-119.00%	N/A

Latest JSPR, GANX, ATRA, and ACET Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	$0.04	0.48%	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
ATRA Atara Biotherapeutics	N/A	1.98	1.98
GANX Gain Therapeutics	0.02	4.36	4.36
JSPR Jasper Therapeutics	N/A	2.26	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
ATRA Atara Biotherapeutics	70.90%
GANX Gain Therapeutics	11.97%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
ATRA Atara Biotherapeutics	41.20%
GANX Gain Therapeutics	4.15%
JSPR Jasper Therapeutics	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	90	9.36 million	9.04 million	Optionable
ATRA Atara Biotherapeutics	330	9.01 million	5.30 million	No Data
GANX Gain Therapeutics	20	43.64 million	41.83 million	Optionable
JSPR Jasper Therapeutics	20	28.00 million	27.35 million	Optionable

JSPR, GANX, ATRA, and ACET Headlines

Recent News About These Companies

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

August 16 at 4:21 AM | americanbankingnews.com

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 15 at 4:36 AM | finanznachrichten.de

Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at Piper Sandler

August 15 at 3:42 AM | americanbankingnews.com

Jasper Therapeutics (NASDAQ:JSPR) Cut to Sell at Wall Street Zen

August 15 at 1:12 AM | americanbankingnews.com

Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates

August 14 at 3:11 PM | blockonomi.com

Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition

August 14 at 11:30 AM | quiverquant.comQ

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 14 at 11:00 AM | globenewswire.com

Jasper Therapeutics (JSPR) Projected to Post Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst

August 6, 2026 | tipranks.com

Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know

August 6, 2026 | tipranks.com

Jasper Therapeutics Completes Kira Acquisition and PIPE Financing

July 19, 2026 | theglobeandmail.com

Jasper Therapeutics, Inc. Announces Merger with Kira Pharmaceuticals

July 17, 2026 | finanznachrichten.de

Jasper Therapeutics Merges With Kira Pharmaceuticals

July 17, 2026 | marketwatch.com

Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition and Announces $132 Million Private Placement and KP-301/KP-402 Out-Licensing to Mirador Therapeutics

July 16, 2026 | quiverquant.comQ

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

July 16, 2026 | globenewswire.com

Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway

July 8, 2026 | theglobeandmail.com

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

June 3, 2026 | zacks.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (JSPR) and Corbus Pharmaceuticals (CRBP)

June 2, 2026 | theglobeandmail.com

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

June 1, 2026 | globenewswire.com

Jasper Therapeutics Announces Board Resignation and Committee Change

May 21, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, GANX, ATRA, and ACET Company Descriptions

Adicet Bio NASDAQ:ACET

$8.38 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$8.36 -0.02 (-0.18%)

As of 08/14/2026 07:34 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Atara Biotherapeutics NASDAQ:ATRA

$8.09 0.00 (0.00%)

As of 08/14/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Gain Therapeutics NASDAQ:GANX

$2.12 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.14 +0.02 (+0.94%)

As of 08/14/2026 07:38 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Jasper Therapeutics NASDAQ:JSPR

$0.79 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.75 -0.04 (-4.57%)

As of 08/14/2026 07:46 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JSPR, GANX, ATRA, and ACET Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JSPR, GANX, ATRA, and ACET Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JSPR, GANX, ATRA, and ACET Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, GANX, ATRA, and ACET Company Descriptions

Adicet Bio NASDAQ:ACET

Atara Biotherapeutics NASDAQ:ATRA

Gain Therapeutics NASDAQ:GANX

Jasper Therapeutics NASDAQ:JSPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JSPR, GANX, ATRA, and ACET Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JSPR, GANX, ATRA, and ACET Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JSPR, GANX, ATRA, and ACET Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, GANX, ATRA, and ACET Company Descriptions

Adicet Bio NASDAQ:ACET

Atara Biotherapeutics NASDAQ:ATRA

Gain Therapeutics NASDAQ:GANX

Jasper Therapeutics NASDAQ:JSPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools